Personalized Cancer Treatment Platform using AI, IoT, and Blockchain

A comprehensive system integrating a growth hormone antagonist and anti-cancer composition with AI, IoT, and blockchain technologies for personalized cancer treatment planning, real-time monitoring, and secure data sharing.

The original patent disclosed a combination therapy for treating cancer using a growth hormone antagonist and anti-cancer composition. However, it lacked personalized treatment planning, real-time monitoring, and secure data sharing capabilities. The new inventive concept addresses these limitations by integrating AI, IoT, and blockchain technologies to provide a more effective and efficient cancer treatment platform.

The system comprises a growth hormone antagonist and an anti-cancer composition, which are integrated with an AI module for personalized cancer treatment planning. The AI module analyzes patient data, medical history, and genomic information to provide tailored treatment recommendations. The system also includes an IoT-enabled device for real-time monitoring of patient response, enabling healthcare providers to adjust treatment plans accordingly. Furthermore, a blockchain-based platform is used for securely storing and sharing medical records, ensuring secure access to treatment data for healthcare providers and researchers. Additionally, the growth hormone antagonist can be conjugated to a nanoparticle made of a novel, biocompatible material for enhanced targeted delivery.

The new claims introduce the integration of AI, IoT, and blockchain technologies with the growth hormone antagonist and anti-cancer composition, providing a novel and non-obvious solution for personalized cancer treatment. The inventive step lies in the synergistic combination of these distinct technologies to create a more effective and efficient cancer treatment platform.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT devices, or blockchain platforms. Additionally, the growth hormone antagonist could be replaced with other cancer treatment agents, or the nanoparticle material could be modified to enhance targeted delivery.

The personalized cancer treatment platform has significant commercial potential in the healthcare industry, particularly in the areas of cancer treatment, personalized medicine, and digital health. The platform could be marketed to healthcare providers, pharmaceutical companies, and research institutions, offering a competitive advantage in cancer treatment and research.